Viking Therapeutics (VKTX) plunged 42% after Phase 2 data on its oral weight loss pill VK2735 sparked safety concerns, despite meeting key endpoints. Analysts at Leerink, Jefferies, Stifel, and HC Wainwright defended the stock, calling the selloff 'overdone' and noting class-leading efficacy with room to optimise tolerability. Retail sentiment on Stocktwits was 'extremely bullish'.